Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Hossam Elzawawy, MD, MS is a board-certified rheumatologist at Cleveland Clinic in Florida, Associate Professor of Medicine at St. George's University and Assistant Professor of Medicine at Charles E. Schmidt College of Medicine, Florida Atlantic University who specializes in the treatment of rheumatoid arthritis, psoriatic arthritis, lupus, gout, vasculitis, ankylosing spondylitis, polymyositis and scleroderma. He received his medical degree at Ain Shams University School of Medicine, Cairo, Egypt in 1995 and trained in Orthopaedics from 1997 to 2000. He was appointed as an Assistant Lecturer of Orthopaedics at Ain Shams University. In 2000, he received a Master's Degree in Orthopaedics.
From 2001 to 2004, Dr. Elzawawy was a Post-Doctoral Research Fellow at Washington University School of Medicine in St. Louis, MO. Dr. Elzawawy's research focused on bone fracture and ligament healing. From 2004-2007, Dr. Elzawawy completed Internal Medicine residency at St. Vincent's Medical Center a major affiliate of the University of Connecticut. In 2007, he joined Cleveland Clinic in Cleveland, OH and completed Rheumatology fellowship in 2009. During his fellowship Dr. Elzawawy investigated hyaluronate as a marker of inflammation in patients with rheumatoid arthritis. Dr. Elzawawy is an active member of the American College of Rheumatology. He had numerous presentations to nationally recognized organizations including the American College of Rheumatology and the Orthopaedic Research Society. He has publications in the Journal of Orthopaedic Research, Journal of Biomechanics, Arthritis Advisor and the Cleveland Clinic Journal of Medicine. He is certified by the American Board of Internal Medicine with a sub-specialty in Rheumatology.
Arthritis, bursitis, gout, infusion therapy, joint aspiration, joint injections
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 4/1/2015, Dr. Elzawawy has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.